Analysts’ revenue estimates
Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.9 billion in fiscal 4Q17, a rise of ~4% compared to its fiscal 4Q16 revenue of $7.6 billion.
On May 25, 2017, Medtronic will announce its fiscal 4Q17 earnings and its fiscal 2017 earnings for the year ended April 28, 2017. Wall Street expects the company’s fiscal 4Q17 revenue to be ~$7.9 billion, a rise of ~4% YoY (year-over-year). The company’s fiscal 3Q17 revenue was ~$7.3 billion, a rise of ~5% YoY.
The above graph shows a comparison of Medtronic’s actual reported revenues and analysts’ estimates in recent quarters. In fiscal 3Q17, Medtronic’s actual revenue exceeded analysts’ expectations due to the strong performances of all four of its business segments. However, the company failed to meet analysts’ expectations in fiscal 2Q17.
Medtronic earns its revenue through operations across four business segments around the globe. It manufactures and sells device-based medical therapy devices across the following four business segments:
- Cardiac and Vascular Group
- Minimally Invasive Therapies Group
- Restorative Therapies Group
- Diabetes Group
For an overview of these segments, read A Key Breakdown of Medtronic’s Business Model.
Among Medtronic’s major competitors, Stryker (SYK), Johnson & Johnson (JNJ), and Becton, Dickinson and Company (BDX) registered revenues of ~$3.0 billion, $17.8 billion, and $3.0 billion, respectively, in their most recent quarters.
Investors interested in gaining exposure to Medtronic can consider investing in the iShares Core S&P 500 ETF (IVV). Medtronic accounts for ~0.56% of IVV’s total holdings.
Next, let’s look at Medtronic’s fiscal 4Q17 earnings expectations.